Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract canc...

por Zheng, Zhiwei, Fang, Ling, Cai, Hongfu
Publicado 2023

Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis

por Zhu, Gaofeng, Cai, Hongfu, Zheng, Zhiwei
Publicado 2023

Preoperative Prognostic Nutritional Index Predict Survival in Patients With Resectable Esophageal Squamous Cell Carcinoma

por Zheng, Zhiwei, Zhu, Huide, Cai, Hongfu
Publicado 2022

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 1...

por Zheng, Zhiwei, Lin, Jingrong, Zhu, Huide, Cai, Hongfu
Publicado 2022

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer

por Zheng, Zhiwei, Zhu, Huide, Fang, Ling, Cai, Hongfu
Publicado 2022

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

por Zhang, Longfeng, Hang, Yongfu, Liu, Maobai, Li, Na, Cai, Hongfu
Publicado 2020

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China

por Chen, Ting, Xie, Ruixiang, Zhao, Qiuling, Cai, Hongfu, Yang, Lin
Publicado 2022

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer...

por Zheng, Zhiwei, Yang, Liu, Xu, Siqi, Zhu, Huide, Cai, Hongfu
Publicado 2022

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

por Liu, Maobai, Zhang, Longfeng, Huang, Qishu, Li, Na, Zheng, Bin, Cai, Hongfu
Publicado 2019

Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review

por Li, Na, Zheng, Huanrui, Zheng, Bin, Chen, Chaoxin, Cai, Hongfu, Liu, Maobai
Publicado 2020

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer

por Li, Na, Zheng, Huanrui, Huang, Yanlei, Zheng, Bin, Cai, Hongfu, Liu, Maobai
Publicado 2021

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

por Zhang, Longfeng, Li, Na, Liu, Maobai, Zheng, Bin, Wu, Zhijuan, Cai, Hongfu
Publicado 2021

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

por Cai, Hongfu, Xu, Baohua, Li, Na, Zheng, Bin, Zheng, Zhiwei, Liu, Maobai
Publicado 2021

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma

por Yang, Liu, Cao, Xueqiong, Li, Na, Zheng, Bin, Liu, Maobai, Cai, Hongfu
Publicado 2022

Mehran 2 Contrast-Associated Acute Kidney Injury Risk Score: Is it Applicable to the Asian Percutaneous Coronary Intervention Population?

por Guo, Ying, Xu, Xue, Xue, Yunjing, Zhao, Chunling, Zhang, Xiaohong, Cai, Hongfu
Publicado 2022

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis

por Cao, Xueqiong, Cai, Hongfu, Li, Na, Zheng, Bin, Zheng, Zhiwei, Liu, Maobai
Publicado 2022

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness...

por Cao, Xueqiong, Zhang, Mingming, Li, Na, Zheng, Bin, Liu, Maobai, Song, Xiaobing, Cai, Hongfu
Publicado 2023

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States

por Liu, Maobai, Han, Sijie, Zheng, Bin, Cai, Hongfu, Yang, Jing, Zhuang, Qian, Li, Na
Publicado 2019

Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review an...

por Yang, Liu, Liu, Maobai, Cao, Xueqiong, Li, Na, Zheng, Bin, Deng, Jianhao, Cai, Hongfu
Publicado 2022

Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States

por Li, Na, Lei, Jianying, Zhang, Jiahao, Cai, Hongfu, Zheng, Bin, Yang, Ting, Liu, Maobai, Hu, Jianda
Publicado 2023